IndustryCompany release
NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M
Nervgen Pharma Corp. (NGEN) · Mon 16 Nov 2026
NervGen Pharma, a spinal cord injury-focused biotech listed on Nasdaq, filed unaudited interim financials for the period ended September 30, 2026. Cash rose to C$80.1M from C$22.1M at year-end, mainly from a May 2026 public offering and option and warrant exercises. A C$33.9M unrealized gain on the warrant derivative produced nine-month net income of C$2.5M, even though operating expenses rose to C$30.3M and the company posted a Q3 net loss of C$6.4M.
Company's press release (SEC filing): Nervgen Pharma Corp. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal
Gedeon Richter · Mon 16 Nov 2026
Metagenomi puts hemophilia A editing candidate MGX-001 first in November 2026 deck
🇺🇸 Metagenomi Therapeutics, Inc. (MGX) · Mon 16 Nov 2026
Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027
🇺🇸 Lifeloc Technologies, Inc (LCTC) · Mon 16 Nov 2026
Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow
🇺🇸 Aytu Biopharma, Inc (AYTU) · Mon 16 Nov 2026
Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Glass House Brands more than doubles Q3 revenue to $56.8M as net loss narrows
Glass House Brands Inc. (GLAS) · Mon 16 Nov 2026